Ms. Rasch et al., THE EFFECT OF INITIAL PERIODONTAL THERAPY ON SALIVARY PLATELET-ACTIVATING-FACTOR LEVELS IN CHRONIC ADULT PERIODONTITIS, Journal of periodontology, 66(7), 1995, pp. 613-623
PLATELET-ACTIVATING FACTOR (PAF), a potent phospholipid inflammatory m
ediator, is increased in the mixed saliva of subjects with periodontal
disease and correlates with the extent of oral inflammation. The pres
ent study was designed to provide a longitudinal evaluation of the eff
ect of initial periodontal therapy (home care instruction, prophylaxis
, and scaling/root planing) on salivary PAF levels in chronic adult pe
riodontitis patients (n = 15). Mixed saliva was collected prior to, du
ring, and after initial therapy and was utilized to assess PAF levels
after lipid extraction and fractionation as well as to histologically
assess the number of polymorphonuclear leukocytes (PMN). PAF activity
was determined in bioassay relative to authentic PAF 1-O-hexadecyl-2-a
cetyl-sn-glycero-3-phosphocholine 16:0-alkyl-PAF). Initial salivary PA
F levels (12.1 +/- 2.8 pmole equivalents of 16:0-alkyl-PAF/ml saliva;
mean +/- SE) decreased following supragingival plaque control (9.6 +/-
2.4) and were further reduced following scaling and root planing (5.7
+/- 1.4). In parallel, salivary PMN levels were significantly reduced
and clinical estimates of periodontal disease were significantly impr
oved; i.e., there was a decrease in the percentage of sites with both
bleeding on probing (from 46.1 +/- 4.6% of sites at pretreatment to 25
.9 +/- 2.6% after scaling and root planing) and probing depths greater
than or equal to 4 mm (from 16.7 +/- 1.9% of sites to 10.3 +/- 1.2%).
Thus, initial periodontal therapy reduced salivary PAF levels in conc
ert with improvements in clinical estimates of marginal and submargina
l periodontal inflammation suggesting that PAF may participate in infl
ammatory events during periodontal tissue injury and disease.